The enhancements were based on the latest trends in video game development and informed by user insights collected across multiple forums.
The STARS-ADHD trial will evaluate the safety and efficacy of the company's proprietary platform, Project: EVO, for the treatment of children with ADHD.
The company will use the funds to support further development of its product, prepare for a potential FDA clearance, and eventually launch in 2017.
Developed by Akili Interactive Labs, Project: EVO was designed to assess and treat cognitive issues; it adapts the intensity of the game to the player.
The trial will look to measure cognitive and symptom improvement over one month of device play; recruitment will begin toward the end of the year.